J Drucker

Institut de Veille Sanitaire

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Pierre Coursaget

Infectiologie Animale et Santé Publique

A Goudeau

Centre Hospitalier Universitaire de Tours

P Maupas

Institut de Virologie

Bertrand Grenier

Purdue University West Lafayette

Alain Moren

Stockholm University

Robert J. Gerety

Biogen (United States)

Edward Tabor

George Washington University

P Bagros

Université de Tours

Vincent Jarlier

Sorbonne Université

Jean Carlet

CNR de la Résistance aux Antibiotiques

Cooperative Institutions

Inserm

Centre Hospitalier Universitaire de Tours

Université Paris Cité

Assistance Publique – Hôpitaux de Paris

Institut de Veille Sanitaire

Université de Tours

Sorbonne Université

Bretonneau Hospital

Institut Pasteur

National Institutes of Health

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Current epidemiology of Staphylococcus aureus with decreased susceptibility to glycopeptides (vancomycin and teicoplanin) in France

Deleted Journal (2000)

Vincent Jarlier J Drucker Patrice Courvalin Jean Carlet J. Etienne

Teicoplanin

10.2807/esw.04.27.01572-en

Cite

Citations (0)

Depression in a medical setting.

PubMed (1980)

J Drucker J Heefner Russell M. Wilder

Depression

Source

Cite

Citations (0)

Bacterial resistance to antibiotics in France : a public health priority

Eurosurveillance (2000)

H Aubry Damon Jean Carlet Patrice Courvalin J C Desenclos J Drucker

For a few years, France has been faced to a rapid spread of anti-microbial resistance in hospitals and in general practice despite the many recommendations issued to solve this problem. In 1999, the Institut de Veille Sanitaire conducted a collective expe

10.2807/esm.05.12.00019-en

Cite

Citations (9)

Transmission du virus HIV 1 de la mere a l'enfant a brazzaville (Congo)

Médecine et Maladies Infectieuses (1988)

Marc Lallemant S. Lallemant-Coeur Dominique Cheynier S Nzingoula Gonzague Jourdain

10.1016/s0399-077x(88)80392-5

Cite

Citations (0)

HBsAg-negative chronic active hepatitis related to hepatitis B virus

Medical Microbiology and Immunology (1978)

A Goudeau Pierre Coursaget J Drucker P Maupas Ph. Borie

Hepatitis B

Complement fixation test

Chronic liver disease

Liver disease

10.1007/bf02121155

Cite

Citations (0)

[Rubella vaccine coverage and seroprotection in 11-year-old children in the Indre-et-Loire department].

PubMed (1994)

C. Bourderioux B. Hubert Sylviane Vol M Feyt J Drucker

Rubella vaccine

Measles-Mumps-Rubella Vaccine

Source

Cite

Citations (3)

La réponse de santé publique à la menace du bioterrorisme aux États‐Unis

Environnement Risques & Sante (2004)

J Drucker

Deux ans apres les attentats du 11 septembre 2001 et l’epidemie de charbon d’origine criminelle, les Etats‐Unis ont renforce leur dispositif de sante publique dans le cadre d’une politique ambitieuse de lutte contre le bioterrorisme. Un effort considerable est consenti par la nation pour la recherche et le developpement de vaccins, de traitements contre les maladies infectieuses epidemiques, pour la veille sanitaire et pour renforcer la capacite de reponse aux urgences de sante publique au niveau des Etats.

Source

Cite

Citations (0)

The different types of epidemiological study

Cahiers d'études et de recherches francophones / Santé (1992)

J Drucker Alain Moren François Dabis

- Les enquetes d’observation cast-emoins et de cohorte sont les outils de base de l’epidemiologiste. - Chaque type d’enquete a des avantages et des inconvenients. La decision d’adopter l’une ou l’autre methodologie depend du facteur de risque et de la maladie etudies, du jugement de l’epidemiologiste, ainsi que des moyens qui seront a sa disposition. - En pratique, on commence en general l’etude d’une relation facteur de risque-maladie par une enquete cas-temoins et l’on poursuit avec une enquete de cohorte si l’on juge necessaire ou souhaitable de confirmer les resultats de l’enquete cas-temoins. - En dehors des etudes experimentales, la mise en evidence d’une association entre le facteur de risque et la maladie ne permet pas de conclure de facon absolue a l’existence d’une relation causale. Cependant, la satisfaction de plusieurs des criteres de causalite permet d’affirmer, avec une tres forte probabilite, l’existence d’une relation causale. Dans de nombreuses circonstances, l’enquete epidemiologique d’observation constitue l’etape ultime de l’etude d’une telle relation, lorsque l’approche experimentale s’avere impraticable.

Source

Cite

Citations (0)

Absence of an Association Between Past Infection with Hepatitis A Virus and Primary Hepatocellular Carcinoma

International Journal of Epidemiology (1980)

Edward Tabor Dimitri Trichopoulos Orestis Manousos X Zavitsanos J Drucker

Tabor E [Hepatitis Branch, Division of Blood and Blood Products, Bureau of Biologics, Food and Drug Administration, Bethesda, MD, 20205, USA), Trichopoulos D, Manousos O, Zavitsanos X, Drucker JA and Gerety RJ. Absence of an association between past infection with hepatitis A virus and primary hepatocellular carcinoma. International Journal of Epidemiology 1980, 9: 22–1223. Serum samples from 77 Caucasians of Greek origin with primary hepatocellular carcinoma (PHC) and 77 age- and sex-matched controls were tested for antibody to the hepatitis A virus (anti-HAV). Anti-HAV was detected in 63 patients with PHC (82%) and in 70 controls (91%). These data suggest that past infection with hepatitis A virus is not related to the development of PHC, in marked contrast to the strong association between PHC and HBV.

Hepatitis virus

10.1093/ije/9.3.221

Cite

Citations (5)

Hepatitis B Vaccine: Efficacy in High-Risk Settings, a Two-Year Study

Intervirology (1978)

Philippe Maupas A Goudeau Pierre Coursaget J Drucker P Bagros

A formalin-treated hepatitis B vaccine in the form of purified hepatitis B surface antigen (HBsAg) was prepared from asymptomatic human HBsAg carriers. Its safety and potency were tested in 5 chimpanzees. The vaccine was administered to 264-individuals. The results of the first 173 immunizations--46 hemodialysis patients and 127 staff members--are presented. Potency was ascertained and efficacy assessed by the development of humoral immune responses to HBsAg (anti-HBs antibody) and seroepidemiologic studies of vaccinated and nonvaccinated subjects. The results, 2 years after immunization, suggest that the vaccine was protective against hepatitis B infection in high-risk hemodialysis settings. Preliminary studies with an inactivated hepatitis B vaccine similarly prepared, but with aluminum hydroxide as adjuvant, indicate that a such a preparation induces a more rapid and stronger anti-HBs response.

Hepatitis B

Hepatitis B vaccine

Asymptomatic carrier

10.1159/000148983

Cite

Citations (50)